GlobeNewswire Inc.··Schall Law FirmSoleno Therapeutics Faces Securities Fraud Lawsuit Over Clinical Trial Disclosures
Schall Law Firm filed securities fraud class action against $SLNO for allegedly concealing safety concerns in Phase 3 DCCR trial. Investors eligible through November 4, 2025.
SLNOsecurities fraudclass action lawsuit